Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases.

O'Reilly MA, Chinnery T, Yee ML, Wu SK, Hynynen K, Kerbel RS, Czarnota GJ, Pritchard KI, Sahgal A.

Sci Rep. 2018 Jun 13;8(1):9013. doi: 10.1038/s41598-018-27335-y.

2.

Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.

Reguera-Nuñez E, Man S, Xu P, Kerbel RS.

Angiogenesis. 2018 Nov;21(4):793-804. doi: 10.1007/s10456-018-9623-8. Epub 2018 May 21.

PMID:
29786782
3.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x. [Epub ahead of print] Review.

4.

Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.

Mastri M, Lee CR, Tracz A, Kerbel RS, Dolan M, Shi Y, Ebos JML.

Mol Cancer Ther. 2018 Jul;17(7):1602-1612. doi: 10.1158/1535-7163.MCT-17-1066. Epub 2018 Apr 25.

PMID:
29695634
5.

Non-angiogenic tumours and their influence on cancer biology.

Donnem T, Reynolds AR, Kuczynski EA, Gatter K, Vermeulen PB, Kerbel RS, Harris AL, Pezzella F.

Nat Rev Cancer. 2018 May;18(5):323-336. doi: 10.1038/nrc.2018.14. Epub 2018 Mar 9. Review.

PMID:
29520090
6.

Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors.

Kuczynski EA, Krueger J, Chow A, Xu P, Man S, Sundaravadanam Y, Miller JK, Krzyzanowski PM, Kerbel RS.

Mol Cancer Ther. 2018 Apr;17(4):869-882. doi: 10.1158/1535-7163.MCT-17-1091. Epub 2018 Feb 26.

PMID:
29483207
7.

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Khan KA, Kerbel RS.

Nat Rev Clin Oncol. 2018 May;15(5):310-324. doi: 10.1038/nrclinonc.2018.9. Epub 2018 Feb 13. Review.

PMID:
29434333
8.

Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.

Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS.

Trends Cancer. 2017 Jul;3(7):529-541. doi: 10.1016/j.trecan.2017.05.002. Epub 2017 Jun 10. Review.

PMID:
28718406
9.

A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature.

Khan KA, Kerbel RS.

Cancer Cell. 2017 Apr 10;31(4):469-471. doi: 10.1016/j.ccell.2017.03.009.

10.

The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.

Kerbel RS, Shaked Y.

Cancer Lett. 2017 Aug 1;400:293-304. doi: 10.1016/j.canlet.2017.02.005. Epub 2017 Feb 12. Review.

PMID:
28202353
11.

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.

Kuczynski EA, Kerbel RS.

Chin J Cancer. 2016 Nov 25;35(1):97.

12.

Therapy-activated stromal cells can dictate tumor fate.

Kerbel RS, Shaked Y.

J Exp Med. 2016 Dec 12;213(13):2831-2833. Epub 2016 Nov 23. Review.

13.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.

14.

Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.

Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS.

Sci Rep. 2016 Nov 14;6:36694. doi: 10.1038/srep36694.

15.

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Bocci G, Kerbel RS.

Nat Rev Clin Oncol. 2016 Nov;13(11):659-673. doi: 10.1038/nrclinonc.2016.64. Epub 2016 May 17. Review.

PMID:
27184418
16.

Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.

Wu FT, Man S, Xu P, Chow A, Paez-Ribes M, Lee CR, Pirie-Shepherd SR, Emmenegger U, Kerbel RS.

Cancer Res. 2016 Dec 1;76(23):6988-7000. Epub 2016 Sep 20. Erratum in: Cancer Res. 2017 Apr 1;77(7):1779.

17.

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy.

Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu FT, Miller V, Andrews D, Kerbel RS.

Cancer Res. 2016 Oct 15;76(20):5983-5993. Epub 2016 Aug 28.

18.

Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.

Paez-Ribes M, Man S, Xu P, Kerbel RS.

PLoS One. 2016 Jun 29;11(6):e0158034. doi: 10.1371/journal.pone.0158034. eCollection 2016.

19.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

Pham E, Yin M, Peters CG, Lee CR, Brown D, Xu P, Man S, Jayaraman L, Rohde E, Chow A, Lazarus D, Eliasof S, Foster FS, Kerbel RS.

Cancer Res. 2016 Aug 1;76(15):4493-503. doi: 10.1158/0008-5472.CAN-15-3435. Epub 2016 Jun 20.

20.

Metronomic chemotherapy for triple negative breast cancer?

Di Desidero T, Kerbel RS, Bocci G.

Aging (Albany NY). 2016 Apr;8(4):573-4. doi: 10.18632/aging.100947. No abstract available.

21.

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.

Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.

J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw030. Print 2016 Aug.

22.

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

Kerbel RS.

Neuro Oncol. 2016 Apr;18(4):459-61. doi: 10.1093/neuonc/nov327. Epub 2016 Jan 31. No abstract available.

23.

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.

Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS.

Oncotarget. 2015 Dec 15;6(40):42396-410. doi: 10.18632/oncotarget.6377.

24.

Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.

Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, Chow A, Lee C, Xu P, Man S, Kerbel RS, Ko YJ.

Oncologist. 2015 Dec;20(12):1351-2. doi: 10.1634/theoncologist.2015-0220. Epub 2015 Nov 5.

26.

Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.

Paez-Ribes M, Man S, Xu P, Kerbel RS.

Clin Cancer Res. 2015 Dec 15;21(24):5488-98. doi: 10.1158/1078-0432.CCR-15-0915. Epub 2015 Jul 13.

27.

Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.

Kerbel RS, Grothey A.

Nat Rev Clin Oncol. 2015 Jun;12(6):313-4. doi: 10.1038/nrclinonc.2015.89. Epub 2015 May 12. No abstract available.

PMID:
25963090
28.

Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS.

Cancer Res. 2015 Jun 15;75(12):2510-9. doi: 10.1158/0008-5472.CAN-14-3687. Epub 2015 Apr 23.

29.

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.

Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G, Kerbel RS.

Sci Transl Med. 2015 Apr 8;7(282):282ra50. doi: 10.1126/scitranslmed.3010722.

PMID:
25855496
30.

Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.

Wu FT, Lee CR, Bogdanovic E, Prodeus A, Gariépy J, Kerbel RS.

EMBO Mol Med. 2015 Jun;7(6):770-87. doi: 10.15252/emmm.201404193.

31.

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.

Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS.

Clin Cancer Res. 2015 Feb 15;21(4):808-18. doi: 10.1158/1078-0432.CCR-14-2810. Epub 2014 Dec 18.

32.

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS.

EMBO Mol Med. 2014 Dec;6(12):1561-76. doi: 10.15252/emmm.201403989.

33.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

34.

Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

Cruz-Muñoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD, Kerbel RS.

Angiogenesis. 2014 Jul;17(3):661-73. doi: 10.1007/s10456-014-9422-9. Epub 2014 Feb 26.

35.

Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.

Ardelean DS, Yin M, Jerkic M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M.

Angiogenesis. 2014 Jul;17(3):641-59. doi: 10.1007/s10456-014-9421-x. Epub 2014 Feb 9.

PMID:
24510304
36.

Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.

Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M.

Transl Oncol. 2013 Oct 1;6(5):511-9. eCollection 2013. Review.

37.

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S.

Breast. 2013 Aug;22 Suppl 2:S57-65. doi: 10.1016/j.breast.2013.07.011. Review.

PMID:
24074794
38.

Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.

Ardelean DS, Jerkic M, Yin M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M.

Angiogenesis. 2014 Jan;17(1):129-46. doi: 10.1007/s10456-013-9383-4. Epub 2013 Sep 24.

PMID:
24061911
39.

Drug rechallenge and treatment beyond progression--implications for drug resistance.

Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS.

Nat Rev Clin Oncol. 2013 Oct;10(10):571-87. doi: 10.1038/nrclinonc.2013.158. Epub 2013 Sep 3. Review.

40.

Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.

Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1465-73. doi: 10.1210/jc.2013-1364. Epub 2013 Aug 22.

PMID:
23969186
41.
42.

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.

Di Matteo P, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi GP.

Br J Cancer. 2013 Jul 23;109(2):360-9. doi: 10.1038/bjc.2013.347. Epub 2013 Jul 4.

43.

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U.

Invest New Drugs. 2014 Feb;32(1):47-59. doi: 10.1007/s10637-013-9974-3. Epub 2013 Jun 2.

PMID:
23728939
44.

Development and characterization of a clinically relevant mouse model of melanoma brain metastasis.

Morsi A, Gaziel-Sovran A, Cruz-Munoz W, Kerbel RS, Golfinos JG, Hernando E, Wadghiri YZ.

Pigment Cell Melanoma Res. 2013 Sep;26(5):743-5. doi: 10.1111/pcmr.12114. Epub 2013 Jun 4. No abstract available.

45.

A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

Guerin E, Man S, Xu P, Kerbel RS.

Cancer Res. 2013 May 1;73(9):2743-8. doi: 10.1158/0008-5472.CAN-12-4183. Epub 2013 Apr 22.

46.

Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles.

Todorova M, Agache V, Mortazavi O, Chen B, Karshafian R, Hynynen K, Man S, Kerbel RS, Goertz DE.

Int J Cancer. 2013 Jun 15;132(12):2956-66. doi: 10.1002/ijc.27977. Epub 2013 Jan 10.

47.

Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

Kerbel RS.

J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):229-39. doi: 10.1007/s10911-012-9266-0. Epub 2012 Sep 26. Review.

PMID:
23011602
48.

Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.

Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS.

Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008-5472.CAN-12-2194. Epub 2012 Aug 3.

49.

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.

Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS.

Gut. 2013 Feb;62(2):259-71. doi: 10.1136/gutjnl-2011-301585. Epub 2012 Apr 28.

50.

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.

Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G.

Angiogenesis. 2012 Jun;15(2):275-86. doi: 10.1007/s10456-012-9260-6. Epub 2012 Mar 2.

Supplemental Content

Loading ...
Support Center